Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X about a recent article by Rohit Thummalapalli et al. published in JCO Precision Oncology:
“A breakthrough moment in high-grade neuroendocrine oncology.
This new JCO Precision Oncology analysis positions DLL3 as one of the most compelling biomarkers in aggressive GEP-NEN biology.
DLL3 expression is markedly enriched in G3 PanNETs and GEP-NECs, tightly linked to higher Ki-67 and inferior outcomes — defining a distinct, targetable phenotype.
Most strikingly, DLL3-immunoPET successfully visualized metastatic lesions, establishing DLL3 as a true theranostic axis with real translational potential. A powerful step toward DLL3-directed imaging and therapy in our most challenging NEN subtypes.”
Title: Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Authors: Rohit Thummalapalli, Salomon Tendler, Joanne Chou, Zeynep Tarcan, Courtney Porfido, Jonathan Willner, Irina Linkov, Umesh Bhanot, Alissa Cooper, Jierui Xu, James Harding, Natasha Rekhtman, Laura Tang, Charles Rudin, Yelena Janjigian, Heiko Schöder, John Porier, Jinru Shia, Olca Basturk, Diane Reidy-Lagunes, Marinela Capanu, Jason Lewis, Lisa Bodei, Mark Dunphy, Nitya Raj
Read the Full Article on JCO Precision Oncology
More posts featuring Aya Mohamed.
